Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA6 | P23280 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | CASP2 | P42575 | 2/20 | 0.55 |
| ▸ | F13A1 | P00488 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | THPO | P40225 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841897 | 0.93 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19840413 | 0.93 | CA12 (0.52) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19841886 | 0.88 | CA12 (0.52) | CA12CA6CA7CA9CA14 | |
| SCHEMBL27377619 | 0.84 | CA12 (0.43) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19862737 | 0.83 | CA12 (0.57) | CA12CA6CA7CA9CA14 | |
| SCHEMBL20664132 | 0.82 | CA12 (0.46) | CA12CA6CA7CA9CA14 | |
| SCHEMBL9437053 | 0.82 | CA12 (0.46) | CA12CA6CA7CA9CA14 | |
| SCHEMBL829645 | 0.82 | CYP2D6 (0.37) | CA12CA6CA7CA9CA14 | |
| SCHEMBL48727 | 0.82 | CYP2D6 (0.41) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19866281 | 0.81 | CASP2 (0.62) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | CA12 704/4885CA6 422/4885CA7 1440/4885 |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | PBK, MICA, STAT3 | CA12 3289/4885CA6 3564/4885CA7 4222/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | CA12 1062/4885CA6 1100/4885CA7 1694/4885 |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | POLRMT, HDGF, PCNP | CA12 1062/4885CA6 1100/4885CA7 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.